The global tumor ablation market size was estimated at USD 2.14 billion in 2025 and is projected to reach USD 6.10 billion by 2033, growing at a CAGR of 14.1% from 2026 to 2033. Ablation is a treatment that destroys tumors without removing them.
This technique is useful in patients with a few small tumors and, at times, when surgery is not an option. Moreover, patients getting this type of treatment do not need to stay in the hospital, thereby increasing the adoption rate of ablation systems among individuals. Rise in the prevalence of various types of cancers, such as those of breast, colon, prostate, and lung, is anticipated to boost the demand for ablation technologies for the treatment of tumors in the kidney, soft tissue, liver, and bone. Cancer is considered a universal healthcare problem, as it is one of the leading causes of death. For instance, according to the National Center for Health Statistics, in 2023, almost 1,958,310 new cancer cases and 609,820 cancer deaths were estimated in the U.S.
Moreover, the increase in the geriatric population in the Asia Pacific region, especially in countries with large untapped opportunities, such as Japan, India, and China, is expected to drive the market over the forecast period. Furthermore, elderly people (aged ≥65) are currently the fastest-growing group among the general population in the U.S. According to the U.S. Census Bureau’s 2017 National Population Projections, by 2060, nearly one in four U.S. citizens is likely to be an older adult. According to the same source, by 2030, all baby boomers are expected to be older than 65.
Technological advancements in ablation devices have facilitated accuracy, portability, and cost-effectiveness, encouraging market players to launch and improve advanced devices constantly. Irreversible electroporation, High-intensity focused ultrasound (HIFU), cryoablation, and image-guided equipment are some of the major examples of technological advancements in the market. Alterations in existing technologies and the introduction of novel ablation techniques make it possible to treat larger & more complex tumors in other organs. Furthermore, developments in intraprocedural imaging aim to increase treatment quality and minimize complications. Hence, advancements in intraprocedural imaging have improved treatment preparation and offer accurate assessment of the ablation zone during treatment.
Several market participants aim to develop and launch novel ablation devices to maintain strong positions in the market, and several ablation systems are receiving regulatory approval from the U.S. FDA. For instance, in September 2022, the U.S. FDA granted 510(k) clearance to Stryker’s OptaBlate bone tumor ablation system (OptaBlate), according to a statement from Stryker. With the inclusion of OptaBlate technology in its portfolio, company’s Interventional Spine (IVS) portfolio now offers a full range of therapeutic options for metastatic vertebral body fractures, expanding on its core capabilities in vertebral augmentation and Radiofrequency Ablation (RFA).
Moreover, demand for minimally invasive procedures is increasing as they result in lower trauma to the patient and facilitate quicker recovery compared to invasive procedures. No incision is required in a tumor ablation procedure, making it noninvasive. Another factor driving the demand for minimally invasive surgeries is the risk of infection during open surgeries. Noninvasive methods decrease hospital stays by saving time and medical costs. Furthermore, a rise in the aging population and the prevalence of obesity is expected to boost market growth. According to the World Health Organization (WHO), 1 in 6 people worldwide will be 60 years or above by 2030. Thes efcators are collectively contributing to the growth of tumor ablation market.
This product will be delivered within 1-3 business days.
This technique is useful in patients with a few small tumors and, at times, when surgery is not an option. Moreover, patients getting this type of treatment do not need to stay in the hospital, thereby increasing the adoption rate of ablation systems among individuals. Rise in the prevalence of various types of cancers, such as those of breast, colon, prostate, and lung, is anticipated to boost the demand for ablation technologies for the treatment of tumors in the kidney, soft tissue, liver, and bone. Cancer is considered a universal healthcare problem, as it is one of the leading causes of death. For instance, according to the National Center for Health Statistics, in 2023, almost 1,958,310 new cancer cases and 609,820 cancer deaths were estimated in the U.S.
Moreover, the increase in the geriatric population in the Asia Pacific region, especially in countries with large untapped opportunities, such as Japan, India, and China, is expected to drive the market over the forecast period. Furthermore, elderly people (aged ≥65) are currently the fastest-growing group among the general population in the U.S. According to the U.S. Census Bureau’s 2017 National Population Projections, by 2060, nearly one in four U.S. citizens is likely to be an older adult. According to the same source, by 2030, all baby boomers are expected to be older than 65.
Technological advancements in ablation devices have facilitated accuracy, portability, and cost-effectiveness, encouraging market players to launch and improve advanced devices constantly. Irreversible electroporation, High-intensity focused ultrasound (HIFU), cryoablation, and image-guided equipment are some of the major examples of technological advancements in the market. Alterations in existing technologies and the introduction of novel ablation techniques make it possible to treat larger & more complex tumors in other organs. Furthermore, developments in intraprocedural imaging aim to increase treatment quality and minimize complications. Hence, advancements in intraprocedural imaging have improved treatment preparation and offer accurate assessment of the ablation zone during treatment.
Several market participants aim to develop and launch novel ablation devices to maintain strong positions in the market, and several ablation systems are receiving regulatory approval from the U.S. FDA. For instance, in September 2022, the U.S. FDA granted 510(k) clearance to Stryker’s OptaBlate bone tumor ablation system (OptaBlate), according to a statement from Stryker. With the inclusion of OptaBlate technology in its portfolio, company’s Interventional Spine (IVS) portfolio now offers a full range of therapeutic options for metastatic vertebral body fractures, expanding on its core capabilities in vertebral augmentation and Radiofrequency Ablation (RFA).
Moreover, demand for minimally invasive procedures is increasing as they result in lower trauma to the patient and facilitate quicker recovery compared to invasive procedures. No incision is required in a tumor ablation procedure, making it noninvasive. Another factor driving the demand for minimally invasive surgeries is the risk of infection during open surgeries. Noninvasive methods decrease hospital stays by saving time and medical costs. Furthermore, a rise in the aging population and the prevalence of obesity is expected to boost market growth. According to the World Health Organization (WHO), 1 in 6 people worldwide will be 60 years or above by 2030. Thes efcators are collectively contributing to the growth of tumor ablation market.
Global Tumor Ablation Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, the analyst has segmented the global tumor ablation market report based on technology, treatment, application, and region:Technology Outlook (Revenue, USD Million, 2021-2033)
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- HIFU
- Other Ablation Technologies
Treatment Outlook (Revenue, USD Million, 2021-2033)
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
Application Outlook (Revenue, USD Million, 2021-2033)
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer
Region Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Tumor Ablation Market Variables, Trends & Scope
Chapter 4. Tumor Ablation Market: Technology Estimates & Trend Analysis
Chapter 5. Tumor Ablation Market: Treatment Estimates & Trend Analysis
Chapter 6. Tumor Ablation Market: Application Estimates & Trend Analysis
Chapter 7. Tumor Ablation Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Tumor Ablation market report include:- Medtronic plc
- Boston Scientific Corporation
- Johnson & Johnson Service Inc. (Ethicon, Inc.)
- AngioDynamics
- Bioventus Inc. (Misonix Inc.)
- EDAP TMS
- Chongqing Haifu Medical Technology Co., Ltd
- Mermaid Medical
- HealthTronics, Inc.
- H.S. Hospital Service S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 170 |
| Published | January 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.14 Billion |
| Forecasted Market Value ( USD | $ 6.1 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
